David Platt, PhD | CEO and Chairman of the Board

Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to Oxygen Therapeutics Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.

Yuval Kwintner, BS, MBA, LLB | President

Mr. Kwintner is an experienced entrepreneur and business executive with proven capabilities and success in both established organizations and start-up ventures.  He is experienced in developing and implementing innovative business strategies, securing investment opportunities and financing and handling all aspects of company operations and corporate transactions.   Mr. Kwintner was the founder of two successful start-up companies.  He was the President of BananaLogix Inc., an emerging company in the nutraceuticals space that developed a unique all-natural supplement that significantly reduced high blood pressure without the side effects of traditional hypertension drugs.  He was also the CEO of VeriBrands LLC, a distributor of a full line of high-quality medical devices.  Prior to that, Mr. Kwintner was a Strategic Planning Manager at Way Systems, Inc., a pioneer in mobile POS solutions and gateway services for mobile merchants, which was later acquired by Verifone.  Mr. Kwintner began his career as an industrial engineer in the Israeli Navy and subsequently practiced business and corporate law in Israel.  Mr. Kwintner earned an M.S. in Management of Technology (MBA equivalent) from MIT Sloan School of Management, an LL.B. from Tel Aviv University School of Law and a B.S. in Industrial Engineering & Management from the Technion – Israel Institute of Technology. 

Dale H. Conaway, DVM | Director

Mr. Conaway, a director of the company since September 2009, is the Veterinary Medical Officer for the Office of Research Oversight, an office within the Veterans Health Administration under the US Department of Veterans Affairs. From 2001 to 2006, Dr. Conaway was the Deputy Regional Director (Southern Region). From 1998 to 2001, Dr. Conaway served as Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories for the Michigan Department of Agriculture. From 1994 to 1998, he was Regulatory Affairs Manager for the Michigan Department of Public Health Vaccine Production Division. From May 2001 to February 2009, Dr. Conaway was a director of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US. Dr. Conaway received a DVM degree from Tuskegee Institute and an MS degree in pathology from the College of veterinary medicine at Michigan State University.

Henry J. Esber, PhD | Director

Mr. Esber, a director of the company since December 2011, has been a principal in Esber D&D consulting since 2005. From 2003 to 2005, Dr. Esber was a Senior Consultant, Business Development at Charles River Labs, Discovery and Development Services. From 2005 to 2006, Dr. Esber was a consultant and from 2006, he was Senior Vice President and Chief Business Officer for Bio-Quant, which he had co-founded. Dr. Esber was also the co-founder of BioSignature Diagnostics, Inc. and Advanced Drug Delivery, Inc. From December 2009 to January 2013, Dr. Esber was a director of Apricus Biosciences, Inc., a public company with shares traded on the NASDAQ Capital Market. From April 2006 to February 2009, Dr. Esber was a director of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US. He serves on the scientific advisory boards of several biotechnology companies and is the author of more than 130 technical publications. Dr. Esber has more than 35 years of experience in the areas of oncology/tumor immunology and immunotherapy as well as strong knowledge in the field of toxicology and regulatory affairs. Dr. Esber received a BS degree in biology/pre-med from the College of William and Mary, an MS degree in public health and parasitology from the University of North Carolina, and a PhD in immunology/microbiology from West Virginia University Medical Center. Dr. Esber was previously a director of the company from September 2009 through December 2010.

Alan M. Hoberman, PhD | Director

Alan M. Hoberman, PhD is president and CEO of Argus International, Inc., overseeing a staff of scientists and other professionals who provide consulting services for industry, government agencies, law firms, and other organizations, both in the U.S. and internationally. Between 1991 and 2013 he held a series of positions of increasing responsibility at Charles River Laboratories Preclinical Services (formerly Argus Research Laboratories, Inc.), most recently as Executive Director of Site Operations and Toxicology. He currently works with that organization to design, supervise, and evaluate reproductive and developmental toxicity, neurotoxicity, inhalation, and photobiology studies. Dr. Hoberman holds a PhD in toxicology from Pacific Western University, an MS in interdisciplinary toxicology from the University of Arkansas, and a BS in biology from Drexel University.